Capstan Therapeutics - About the company
Capstan Therapeutics is an acquired company based in San Diego (United States), founded in 2021. It operates as a Developer of cell therapies for a broad range of diseases. Capstan Therapeutics has raised $340M in funding from investors like Pfizer, RA Capital Management and Novartis Venture Fund, with last known valuation of $*****. The company has 3408 active competitors, including 1138 funded and 788 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of cell therapies for a broad range of diseases. The company's technology comprises targeted lipid nanoparticles (tLNPs), CAR-based immunotherapy, and nucleic acid drug delivery to develop treatment options for patients for oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders.
- Website
- capstantx.com
- Social
- Email ID
- *****@capstantx.com
Key Metrics
Founded Year
2021
Location
San Diego, United States
Stage
Acquired
Total Funding
$340M in 3 rounds
Latest Funding Round
Last Known Valuation
$***** as on Apr 21, 2026
Ranked
680th among 3408 active competitors
Employee Count
85 as on Nov 14, 2025
Exit Details
Acquired by AbbVie (Jul 01, 2025)
Capstan Therapeutics's acquisition details
Click here to take a look at Capstan Therapeutics's acquisition in detail
Sign up to download Capstan Therapeutics' company profile
Capstan Therapeutics's funding and investors
Capstan Therapeutics has raised a total funding of $340M over 3 rounds. Its first funding round was on Nov 24, 2021. Its latest funding round was a Series B round on Mar 05, 2024 for $*****. 15 investors participated in its latest round. Capstan Therapeutics has 16 institutional investors.
Here is the list of recent funding rounds of Capstan Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Mar 05, 2024 | 1730319 | Series B | 3790899 | 9233092 | 3059789 | 8980811 |
Jun 14, 2022 | 3459661 | Series A | 1457959 | 1222900 | 5360376 | |
Nov 24, 2021 | 9370043 | Seed | 7852805 | 6801682 |
Access funding benchmarks and valuations. Sign up today!View details of Capstan Therapeutics's funding rounds and investors
Capstan Therapeutics' founders and board of directors
Founder? Claim ProfileCapstan Therapeutics' employee count trend
Capstan Therapeutics has 85 employees as of Nov 25. Here is Capstan Therapeutics's employee count trend over the years:
Uncover Capstan Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Capstan Therapeutics's Competitors and alternates
Top competitors of Capstan Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Capstan Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
680th |  Capstan Therapeutics 2021, San Diego (United States), Acquired | Developer of cell therapies for a broad range of diseases | $340M | 48/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Capstan Therapeutics's competitors? Click here to see the top ones
Capstan Therapeutics's Investments and acquisitions
Capstan Therapeutics has made no investments or acquisitions yet.
Reports related to Capstan Therapeutics
Here is the latest report on Capstan Therapeutics's sector:
News related to Capstan Therapeutics
Filter this list•
AbbVie Completes Acquisition of Capstan TherapeuticsFinancial Times•Aug 19, 2025•Capstan Therapeutics, AbbVie
•
FORT Robotics Secures $18.9 Million in Series B, Totaling $60.5 Million for Robotics Safety InnovationRoboticstomorrow•Aug 07, 2025•Fort Robotics, John Deere, Tiger Global Management, Neman Ventures and 17 others
•
AbbVie to Acquire Capstan Therapeutics in $2.1B Deal for in vivo CAR-T WorkEndpoints•Jun 30, 2025•AbbVie, Capstan Therapeutics
•
Enabling the Body To Engineer Its Own CAR T CellsTechnology Networks•Jun 20, 2025•Capstan Therapeutics
•
Capstan Therapeutics Presents Preclinical Data on Lead In Vivo CAR-T Candidate, CPTX2309, at American College of Rheumatology (ACR) Convergence 2024Business Wire•Nov 18, 2024•Capstan Therapeutics
•
Capstan Therapeutics to Present Preclinical Data on Lead In Vivo Chimeric Antigen Receptor (CAR)-T Candidate, CPTX2309, at American College of Rheumatology (ACR) Convergence 2024Business Wire•Sep 26, 2024•Capstan Therapeutics
•
Forbion participates in US financing roundsEuropean Biotechnology•Apr 03, 2024•Engrail Therapeutics, Capstan Therapeutics, Forbion, RA Capital Management and 13 others
•
Capstan secures $175m Series B funds for CAR-T therapyPharmaceutical Technology•Mar 21, 2024•Capstan Therapeutics, RA Capital Management, Forbion, Johnson & Johnson Innovation and 13 others
•
Capstan Therapeutics Appoints Ramin Farzaneh-Far, M.D., as Chief Medical Officer and Announces Key Business Leadership PromotionBusiness Wire•Jan 08, 2024•Capstan Therapeutics
•
Capstan Therapeutics Appoints Ramin Farzaneh-Far, M.D., as Chief Medical Officer and Announces Key Business Leadership PromotionBusiness Wire•Jan 08, 2024•Capstan Therapeutics
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Capstan Therapeutics
Explore our recently published companies
- Lingo Scope - 2021 founded, Unfunded company
- Lavi Hendin - Unfunded company
- Axeseo - Unfunded company
- Videospan - Chicago based, 2022 founded, Unfunded company
- ENDOELEKTRONIK.PL SP. Z O.O. SP.K - Poland based, Unfunded company
- JS Hubbuck - Hexham based, 1975 founded, Unfunded company
